An observational study in Nervous System Tumor, sponsored by Institut du Cancer de Montpellier - Val d'Aurelle. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Institut du Cancer de Montpellier - Val d'Aurelle · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
the creation of a clinical database including data for all PCNST patients is of high interest. This database will allow us to develop clinical studies on:
Primary central nervous system tumors (PCNST) correspond to all primitive tumors involving central nervous system structures, meninges and the origin of the cranial and paraspinal nerves. They have a malignant, benign, or borderline evolution. TPSNC represent a heterogeneous group of tumors, with more than 140 subtypes described in the WHO classification. The causes, prognostic factors, and therapeutic management differ according to the histological subtype.
The incidence of all of TPSNCs ranges from 17.6 to 22.0/105 in North American and European studies. However, because of the high number of different histological subtypes, most of them must be considered as rare tumors. Moreover, they represent a major public health problem due to high morbidity [8] and mortality.
In this context, the creation of a clinical database including data for all PCNST patients is of high interest. This database will allow us to develop clinical studies on:
The database will also allow us to develop or participate in multicentric clinical studies, at the national or international level, as well as to facilitate the identification of patients for inclusion in translational studies
19 studies on the registry are indexed under Nervous System Neoplasms; 8 are open to participants now.
Browse Nervous System Neoplasms studies →Institut du Cancer de Montpellier - Val d'Aurelle is the lead sponsor of 142 studies on the registry; 46 are open to participants now.
Counted across the registry records on this site, refreshed daily.
all patient with Primary central nervous system tumors and treated at the Montpellier Cancer Institute
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The information letter will be delivered by the investigator physician to the patients to inform them on the study, its implementation and their complete freedom to participate or not. Clinical Data and Questionnaires: 1. For the retrospective part * Patient identification based on data from the Medical Information Department (DIM) of the ICM; * Verification of the eligibility criteria; * Inclusion of patients in a coded form in BDD-NO; * Implementation of the database with the data already collected (as an coded EXCEL file) in specific studies (some patients are included in several of these studies): study of diffuse low grade gliomas, study on anaplastic gliomas, study on the place of Bevacizumab in high-grade gliomas, clinical database created * Collection of clinical data from each patient's medical record 2. For the prospective part * Inclusion of patients in a coded form in BDD-NO; * Collection of clinical data from each patient's medical record.
Other: data collection
Diagnostic data : date and description of first symptoms,date of radiological diagnosis, tumor localization, number of lesions, date of histological diagnosis, histological diagnostic mode, histological diagnosis, WHO grade (I, II, III or IV), immunohistochemic data, molecular alterations therapeutic sequence : type of treatment, baseline exam before each treatment, surgery, radiothérapy, systemic treatment, clinical study, follow up until death
Establish an exhaustive database of patients treated for a Primary central nervous system tumors at the Montpellier Cancer Institute, whatever the histological subtype and the oncological treatment
collection of clinical data in the medical record
Time frame: From date of inclusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Realization of clinical studies specific to certain histological subtypes to be carried out on the clinical, radiological and biological presentation of patients, specific oncological treatments and toxicities, prognostic factors and survival data
obtaining reliable clinical data for write new clinical trials project
Time frame: From date of inclusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
To allow the realization of epidemiological studies specific to certain histological subtypes
new clinical trials project based on this clinical database
Time frame: From date of inclusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
To facilitate the identification of patients for inclusion in French or European retrospective studies
new clinical trials project based on this clinical database
Time frame: From date of inclusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Plan to share: No
Started Jan 2018 (actual). Primary completion is estimated for Jan 2035, 204 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut du Cancer de Montpellier - Val d'Aurelle →